J McHutchison

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C
    J G McHutchison
    Division of Gastroenterology, Gastrointestinal Hepatology Research Program, Duke Clinical Research Institute, Durham, NC 27715, USA
    Aliment Pharmacol Ther 27:422-32. 2008
  2. pmc Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection
    Ian R White
    Department of Disease and Biomarker Proteomics, GlaxoSmithKline Pharmaceuticals, Stevenage, UK
    J Transl Med 5:33. 2007
  3. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
  4. ncbi request reprint Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
    John G McHutchison
    Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
    N Engl J Med 357:2227-36. 2007
  5. ncbi request reprint Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
    John G McHutchison
    ALT Alliance for Liver Therapy Group, Division of Gastroenterology and Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Hepatology 46:1341-9. 2007
  6. ncbi request reprint Future trends in managing hepatitis C
    John G McHutchison
    Division of Gastroenterology and GI Hepatology Research, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27710, USA
    Gastroenterol Clin North Am 33:S51-61. 2004
  7. ncbi request reprint The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice
    John G McHutchison
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Centre, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27707, USA
    J Hepatol 44:411-21. 2006
  8. ncbi request reprint Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group
    John McHutchison
    GI Hepatology Research, Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Clin Gastroenterol Hepatol 4:1214-1220. 2006
  9. ncbi request reprint Definition and management of anemia in patients infected with hepatitis C virus
    John G McHutchison
    Duke University Medical Center, Durham, NC 27710, USA
    Liver Int 26:389-98. 2006
  10. ncbi request reprint A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:635-43. 2005

Collaborators

Detail Information

Publications72

  1. ncbi request reprint Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C
    J G McHutchison
    Division of Gastroenterology, Gastrointestinal Hepatology Research Program, Duke Clinical Research Institute, Durham, NC 27715, USA
    Aliment Pharmacol Ther 27:422-32. 2008
    ..Treatment options are limited for patients with hepatitis C virus who do not experience sustained viral eradication with pegylated interferon and ribavirin therapy...
  2. pmc Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection
    Ian R White
    Department of Disease and Biomarker Proteomics, GlaxoSmithKline Pharmaceuticals, Stevenage, UK
    J Transl Med 5:33. 2007
    ..To identify potential biomarkers of fibrosis, we compared serum protein expression profiles in patients with chronic hepatitis C (CHC) virus infection and fibrosis...
  3. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
    ..We examined factors that influence the participation of gastroenterologists and hepatologists in clinical research...
  4. ncbi request reprint Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
    John G McHutchison
    Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
    N Engl J Med 357:2227-36. 2007
    ..We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis...
  5. ncbi request reprint Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
    John G McHutchison
    ALT Alliance for Liver Therapy Group, Division of Gastroenterology and Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Hepatology 46:1341-9. 2007
    ..The data support further clinical studies of CPG 10101 for treating chronic HCV infection...
  6. ncbi request reprint Future trends in managing hepatitis C
    John G McHutchison
    Division of Gastroenterology and GI Hepatology Research, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27710, USA
    Gastroenterol Clin North Am 33:S51-61. 2004
    ..Multiple-drug regimens will likely be required to enhance viral clearance and reduce viral resistance, while providing greater tolerability...
  7. ncbi request reprint The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice
    John G McHutchison
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Centre, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27707, USA
    J Hepatol 44:411-21. 2006
  8. ncbi request reprint Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group
    John McHutchison
    GI Hepatology Research, Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Clin Gastroenterol Hepatol 4:1214-1220. 2006
    ..In this article, we summarize those discussions and attempt to highlight many of the hurdles and unanswered questions as we attempt to move forward and develop therapies to combat liver fibrosis...
  9. ncbi request reprint Definition and management of anemia in patients infected with hepatitis C virus
    John G McHutchison
    Duke University Medical Center, Durham, NC 27710, USA
    Liver Int 26:389-98. 2006
    ..Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C...
  10. ncbi request reprint A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:635-43. 2005
    ..Larger, longer duration trials incorporating pegylated IFN would be required to determine whether this combination, alone or with RBV, would increase either early or sustained virological response rates...
  11. ncbi request reprint Chronic hepatitis C: an age wave of disease burden
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Manag Care 11:S286-95; quiz S307-11. 2005
    ..This article reviews the epidemiology, natural history, clinical and economic burden, and screening and treatment options for HCV...
  12. ncbi request reprint A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients
    John G McHutchison
    The Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    J Hepatol 44:88-96. 2006
    ..This Phase I, open-label, dose-escalation trial of ISIS 14803 was performed in chronic HCV patients...
  13. ncbi request reprint Making it happen: managed care considerations in vanquishing hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Am J Manag Care 13:S327-36; quiz S337-40. 2007
    ....
  14. doi request reprint Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  15. ncbi request reprint Future therapy of hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Hepatology 36:S245-52. 2002
    ..Most of these newer therapies are unlikely to be available for routine clinical use in the next 3 to 5 years...
  16. doi request reprint Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection
    John McHutchison
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 138:1365-73, 1373.e1-2. 2010
    ..We evaluated its antifibrotic effect in patients with chronic hepatitis C that did not respond to standard-of-care therapy...
  17. doi request reprint Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C
    J McHutchison
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    J Viral Hepat 15:475-81. 2008
    ..Herein, we present the scientific rationale and study design, discuss key data from other trials, and summarize our expectations of this study...
  18. doi request reprint Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    ..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
  19. ncbi request reprint Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy
    N A Terrault
    Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143 0538, USA
    J Viral Hepat 12:465-72. 2005
    ..Additionally, we demonstrated the need for cautious interpretation of stopping rules when the values are at or near the decision thresholds...
  20. ncbi request reprint The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period
    Ravi Jhaveri
    Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC 27705, USA
    J Pediatr 148:353-8. 2006
    ..To quantify the burden of pediatric hepatitis C virus (HCV) disease over the coming decade...
  21. pmc Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation
    Ravi Jhaveri
    Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 197:283-91. 2008
    ..We hypothesize that specific sequence polymorphisms in HCV genotype 3 core protein may be associated with hepatic intracellular lipid accumulation...
  22. doi request reprint Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    J Antimicrob Chemother 65:2063-9. 2010
    ..Here, we summarize the current information regarding the effectiveness of protease inhibitors in treating chronic HCV and discuss the key challenges now facing the field...
  23. ncbi request reprint Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus
    Alastair D Smith
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Clin Transplant 19:250-4. 2005
    ....
  24. ncbi request reprint A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Liver Unit, Zeidler Ledcor Center, 130 University Campus, Edmonton, Alberta, Canada, T6G 2X8
    J Hepatol 44:671-8. 2006
    ..Recombinant human albumin-interferon alfa (alb-IFN) is a novel 85.7-kD recombinant protein consisting of interferon alfa-2b genetically fused to human serum albumin...
  25. ncbi request reprint Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo
    Rebecca Lim
    School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia
    Hepatology 43:1074-83. 2006
    ..05). In conclusion, interferon alpha-based treatment reduced the number of hepatic progenitor cells in chronic liver injury by modulating apoptosis, proliferation, and differentiation. Supplementay material for this article can..
  26. ncbi request reprint HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 43:241-9. 2006
    ..HLA zygosity at 1, 2, or 3 alleles was not associated with fibrosis stage, liver inflammation, or treatment outcome. In conclusion, HLA class I allelic diversity has a minor influence on FPRs and disease severity in CHC...
  27. ncbi request reprint Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resist
    Muriel Soler
    Departament of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Antivir Ther 9:953-68. 2004
    ..Furthermore, no obvious nucleotide changes in the surrounding IRES region that might possibly affect oligonucleotide binding were detected...
  28. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  29. pmc Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury
    James Rochon
    Duke Clinical Research Institute, Durham, NC 27713, USA
    Hepatology 48:1175-83. 2008
    ..54 (upper 95% confidence limit = 0.77); the interrater reliability was 0.45 (upper 95% confidence limit = 0.58). Categorizing the RUCAM to a five-category scale improved these reliabilities but only marginally...
  30. ncbi request reprint Into the light: strategies for battling hepatitis C
    Bruce R Bacon
    Division of Gastroenterology and Hepatology, Saint Louis University, 3635 Vista Ave, FDT 9th Fl S, St Louis, MO 63110, USA
    Am J Manag Care 13:S319-26. 2007
    ..Future pharmacologic agents are currently in development for patients failing treatment or those who have relapsed...
  31. ncbi request reprint Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients
    Keyur Patel
    Hepatology 37:1222; author reply 1222-3. 2003
  32. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007
    ..Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited...
  33. doi request reprint Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Edmonton, Canada
    Clin Gastroenterol Hepatol 6:701-6. 2008
    ..A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-naïve patients with genotype 2/3, chronic hepatitis C virus infection...
  34. doi request reprint Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
    Stefan Zeuzem
    JW Goethe University Hospital, Frankfurt, Germany
    Hepatology 48:407-17. 2008
    ..At week 12, mean treatment-associated missed workdays were significantly lower with alb-IFN 900 mug q2wk versus PEG-IFNalpha-2a (1.1 versus 4.3 days; P = 0.006)...
  35. ncbi request reprint Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 47:174-82. 2007
    ..To explore safety, pharmacokinetics, and pharmacodynamics of oral administration of resiquimod, a Toll-like receptor 7 and 8 agonist that induces endogenous interferon-alpha, in subjects with chronic hepatitis C virus infection...
  36. ncbi request reprint The hepatitis C virus life cycle as a target for new antiviral therapies
    Jean Michel Pawlotsky
    French National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Hopital Henri Mondor, Universite Paris 12, Creteil, France
    Gastroenterology 132:1979-98. 2007
    ....
  37. ncbi request reprint Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy
    John G McHutchison
    Duke Clinical Research Institute, Division of Gastroenterology Duke University, Durham, North Carolina 27705, USA
    Am J Gastroenterol 102:880-9. 2007
    ..In the meantime, physicians must make the best possible use of the available options for managing anemia, especially in select patient groups who are most at risk for anemia and its complications...
  38. ncbi request reprint Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
    Andrew J Muir
    Hepatology 44:1400-3. 2006
  39. ncbi request reprint Relationship of smoking and fibrosis in patients with chronic hepatitis C
    Anouk Dev
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Gastroenterol Hepatol 4:797-801. 2006
    ..These cytokine levels are increased in animals with cirrhosis and in human beings with CHC. We studied whether the concentrations of VEGF, VEGF-D, s-Flt, and s-KDR were increased in CHC smokers with and without hepatic fibrosis...
  40. doi request reprint Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Gastroenterol Hepatol 6:242-7. 2008
    ..We hypothesized that a noninvasive test of liver fibrosis can accurately stage liver fibrosis. We prospectively evaluated the FIBROSpect II (FSII) biomarker panel versus pathology assessment and a quantitative measure of fibrosis...
  41. ncbi request reprint American Gastroenterological Association technical review on the management of hepatitis C
    Jules L Dienstag
    Gastrointestinal Unit Medical Services Massachusetts General Hospital, Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 130:231-64; quiz 214-7. 2006
  42. ncbi request reprint Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  43. ncbi request reprint Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C
    John B Wong
    Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Gastroenterol 98:2354-62. 2003
    ..The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during antiviral therapy for treatment naive chronic hepatitis C patients...
  44. ncbi request reprint Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  45. ncbi request reprint Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients
    Keyur Patel
    Duke Clinical Research Institute, Division of Gastroenterology, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Postgrad Med 114:48-52, 57-9, 62. 2003
    ....
  46. ncbi request reprint Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
    Keyur Patel
    Hepatology 38:21-4. 2003
  47. ncbi request reprint A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    Hepatology 37:1368-74. 2003
    ..In conclusion, IL-12 as monotherapy at the doses used in this trial for chronic hepatitis C has low efficacy, was poorly tolerated, and is unlikely to provide an alternative to conventional IFN-based therapy...
  48. ncbi request reprint Current therapy for hepatitis C: pegylated interferon and ribavirin
    John G McHutchison
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Clin Liver Dis 7:149-61. 2003
    ....
  49. ncbi request reprint Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Gastroenterol Hepatol 18:253-7. 2003
    ..However, its use in monitoring fibrosis over time has not been established. The aim of the present study was to assess the serial relationships between HA and liver fibrosis before and after treatment...
  50. ncbi request reprint Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  51. ncbi request reprint Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
    Magali Bouvier-Alias
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Hepatology 36:211-8. 2002
    ..Nevertheless, the total HCV core Ag assay cannot be used as a marker of viral replication for HCV RNA values below 20,000 IU/mL, limiting its use in the monitoring of late events during and after antiviral treatment...
  52. ncbi request reprint Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection
    Stephen Pianko
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Interferon Cytokine Res 22:483-9. 2002
    ..IFN monotherapy nonresponder patients tended to have a higher HIC. With IFN plus ribavirin, the sustained virologic response rate was not affected by the HIC...
  53. ncbi request reprint Hepatitis C advances in antiviral therapy: what is accepted treatment now?
    John G McHutchison
    Division of Gastroenterology and Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road, N203, La Jolla, CA 92037, USA
    J Gastroenterol Hepatol 17:431-41. 2002
    ..They will thus provide an incremental benefit in terms of efficacy, particularly for genotype 1-infected patients...
  54. ncbi request reprint Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C
    Hugo R Rosen
    Division of Gastroenterology, Portland VAMC and Oregon Health Sciences University, 97207, USA
    Am J Gastroenterol 97:714-20. 2002
    ....
  55. ncbi request reprint New therapies for chronic hepatitis C virus infection
    Anouk Dev
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Curr Gastroenterol Rep 6:77-86. 2004
    ....
  56. ncbi request reprint Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
    Jean Michel Pawlotsky
    Department of Virology EA 3489, Henri Mondor Hospital, University of Paris XII, Creteil, France
    Hepatology 39:554-67. 2004
  57. ncbi request reprint Risks of a range of alcohol intake on hepatitis C-related fibrosis
    Alexander Monto
    Department of Gastroenterology, University of California at San Francisco, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 39:826-34. 2004
    ..Age, serum ALT, and inflammation are independently associated with fibrosis in multivariate analysis, highlighting the fact that variables other than alcohol intake predominate in the production of hepatic fibrosis...
  58. ncbi request reprint Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin
    Stephen J Rulyak
    Department of Medicine, Division of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Am J Gastroenterol 100:332-7. 2005
    ..The aims of this study were to determine the effect of pretreatment hepatic iron concentration (HIC) on response to combination therapy with interferon and ribavirin, and to examine the change in HIC associated with this treatment...
  59. ncbi request reprint Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    J Hepatol 41:935-42. 2004
    ....
  60. ncbi request reprint Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Cleve Clin J Med 71:S8-12. 2004
    ..Early virologic response is a good predictor of eventual sustained response for patients with HCV genotype 1 infection. Despite important gains in treating chronic hepatitis C, many treatment challenges remain...
  61. ncbi request reprint Hepatitis C and steatosis
    Anouk Dev
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Centre, P O Box 17969, Durham, NC 27715, USA
    Clin Liver Dis 8:881-92, ix. 2004
    ..Research efforts should continue to focus on defining the complex viral and host interactions involved in the pathogenesis of HCV-related steatosis so that future therapeutic strategies may be accurately and appropriately targeted...
  62. ncbi request reprint Population-based hepatitis C surveillance and treatment in a national managed care organization
    Deborah Shatin
    UnitedHealth Group, Center for Health Care Policy and Evaluation, 12125 Technology Drive, MN002 0260, Minneapolis, MN 55344, USA
    Am J Manag Care 10:250-6. 2004
    ..To use a national population-based automated claims database to study the testing rate, prevalence, and prescribing patterns for chronic hepatitis C...
  63. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  64. ncbi request reprint The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:535-41. 2005
    ..We compared the Catrimox-14 WB assay with a standard serum assay...
  65. ncbi request reprint Hepatitis C: a 20-year debt comes due
    John G McHutchison
    Gastroenterology and Hepatology Research, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Manag Care 10:S20. 2004
  66. ncbi request reprint Treatment issues with chronic hepatitis C: special populations and pharmacy strategies
    Bruce R Bacon
    Saint Louis University, Division of Gastroenterology 3635 Vista Ave, St Louis, MO 63110 2539, USA
    Am J Manag Care 11:S296-306; quiz S307-11. 2005
    ....
  67. ncbi request reprint Treatment of acute hepatitis C infection: more pieces of the puzzle?
    Amany Zekry
    J Hepatol 42:293-6. 2005
  68. ncbi request reprint Steatosis and chronic hepatitis C virus infection: mechanisms and significance
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Clin Liver Dis 9:399-410, vi. 2005
    ..This may provide novel future therapeutic strategies that may help modulate disease progression in relation to steatosis in HCV infection...
  69. ncbi request reprint Tinkering and tailoring with HCV therapy: can we get away with less?
    Amany Zekry
    Hepatology 40:1249-51. 2004
  70. ncbi request reprint Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions
    Anouk Dev
    Am J Gastroenterol 98:2344-7. 2003
  71. ncbi request reprint Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C
    G Mani Subramanian
    Human Genome Sciences, Inc, 14200 Shady Grove Road, Rockville, Maryland 21042, USA
    Nat Biotechnol 25:1411-9. 2007
    ..These fusion proteins, which are at present in different phases of clinical development, might lead to improved therapies across a broad range of diseases...
  72. ncbi request reprint Trends in health care resource use for hepatitis C virus infection in the United States
    William C Grant
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 42:1406-13. 2005
    ..In conclusion, as patients continue to age and disease burden progresses, suboptimal decisions regarding HCV treatments will bring increasing opportunity costs for the health care system and society...